PROF logo

PROFOUND MEDICAL CORP

PROFNASDAQ
🏆 #3669 by market capEarnings Oct 29US Equity
$5.73▼ $0.17 (−2.97%)
Market closed · at close
🔔
Track PROF
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 3.0%
7d▼ 0.1%
14d▼ 2.0%
30d▼ 15.8%
ytd▼ 27.6%
1y▲ 14.3%
🏦Market Cap
$208M
Small Cap
📈Revenue Growth (YoY)
+61.1%
High Growth
📊Gross Margin
71.7%
High
💵FCF Margin
-188.7%
Thin
⚖️P/S Ratio
11.3x
Elevated
Otter Score
68
Fair

Trading Snapshot

Day Range
$5.67 – $5.83
52-Week Range
$4.80 – $8.95
Volume
$3.82B
Avg Volume
$4.11B
Shares Outstanding
36.3M
Next Earnings
Nov 4, 2026

Fundamentals Snapshot

Annual Revenue
$16M
Last Q Revenue
$2M
P/E Ratio
-6.1
P/S Ratio
11.3x
EPS (TTM)
$-0.89
Dividend Yield
0.00%
Dilution (1yr)
+19.2%

Why Investors Own PROF

  • ✓High-growth profile — revenue up +30.9% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 77% gross margin and 8% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PROF logo

PROFOUND MEDICAL CORP

PROF
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$16M▲ +61.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
70.8%▲ +7.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$42M▲ +33.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$39M▲ +66.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
30.7M▲ +19.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$75M▲ +$26M YoY
StockOtter · stockotter.space

About PROFOUND MEDICAL CORP

Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Ratings

ⓘ
Consensus
Buy
5 analysts
Strong Buy1
Buy3
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
Bloomberg·2h ago

PROFOUND MEDICAL CORP tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift PROF price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

PROFOUND MEDICAL CORP announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.